Pancreatic cancer drug daraxonrasib nearly doubles median survival in clinical trials
By
The Economist
Summary
Scientists gave a standing ovation at a Chicago conference for clinical trial results of daraxonrasib, a pancreatic cancer drug developed by Revolution Medicines. The drug nearly doubled median survival times from 6.7 months to 13.2 months, marking a significant breakthrough against one of the most challenging cancers. It could represent the first of an entirely new class of treatments.
Source
Twitter / XPancreatic cancer drug daraxonrasib nearly doubles median survival in clinical trialseconomist.comKey quotes
· 3 pulledScientists are not usually an excitable bunch. So when many thousands of them gave a standing ovation at a conference in Chicago, it meant something special had happened.
The drug almost doubled median survival times from 6.7 months to 13.2 months.
This victory over one of the most challenging cancers was an emotional moment for many.
You might also wanna read
Experimental daraxonrasib pill nearly doubles survival time in advanced pancreatic cancer trial
A new experimental pill called daraxonrasib has shown promising results in extending survival for patients with advanced pancreatic cancer.
cnbc.com·1mo ago
Daraxonrasib drug nearly doubles survival in advanced pancreatic cancer, oncologist reports
Pancreatic cancer has extremely low survival rates (97% mortality within 5 years for metastatic cases) due to lack of effective screening an
news.cuanschutz.edu·19d ago
Experimental pill daraxonrasib nearly doubles survival time for advanced pancreatic cancer patients
Researchers reported that daraxonrasib, a novel daily pill, helped people with advanced pancreatic cancer live longer by blocking a mutated
abcnews.com·1mo ago
Experimental pill daraxonrasib nearly doubles survival time in advanced pancreatic cancer trial
A novel experimental pill called daraxonrasib has shown promise in extending survival for patients with advanced pancreatic cancer. The drug
chicagotribune.com·1mo agoExperimental pill daraxonrasib nearly doubles survival time in advanced pancreatic cancer trial
A novel experimental pill called daraxonrasib has shown promise in extending survival for patients with advanced pancreatic cancer. The drug
chicagotribune.com·1mo ago
Experimental pill daraxonrasib nearly doubles survival time in advanced pancreatic cancer patients
A novel experimental pill called daraxonrasib has shown promise in extending survival for patients with advanced pancreatic cancer. The drug
chicagotribune.com·1mo ago
Daraxonrasib nearly doubles survival in advanced pancreatic cancer by targeting previously 'undruggable' mechanism
A new drug called daraxonrasib has shown promise in nearly doubling survival rates for patients with advanced pancreatic cancer. Pancreatic
theconversation.com·1mo ago
Comments
Sign in to join the conversation.
No comments yet. Be the first.